IMMULITE 2000 Systems Total Antibodies to Hepatitis B Core Antigen (Anti-HBc)
Siemens Healthcare Diagnostics Products, Ltd. · Decision date Aug 4, 2025
What did the FDA decide?
FDA records P010051/S023 as a supplement to PMA P010051, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 4, 2025.
FDA approval order statement
an internal site to internal site transfer of a manufacturing process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Aug 4, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P010051/S023
- Regulatory pathway
- PMA supplement
- Product code
- LOM
- Decision code
- OK30
- Decision date
- Aug 4, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen).
- Product code
- LOM
- FDA device class
- 2
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P010051/S023 received
Application receipt date recorded by FDA.
P010051/S023 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P010051. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LOM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| DiaSorin, Inc. | 510(k) clearance | Jun 4, 2026 | FDA | |
Atellica IM Hepatitis B core IgM (aHBcM)P030040/S024 | Siemens Healthcare Diagnostics | PMA supplement | Oct 17, 2025 | FDA |
Atellica IM Hepatitis B e Antigen (HBeAg)P090024/S013 | Siemens Healthcare Diagnostics | PMA supplement | Oct 17, 2025 | FDA |
| Siemens Healthcare Diagnostics, Inc. | PMA supplement | Oct 17, 2025 | FDA | |
| Siemens Corp. | PMA supplement | Oct 17, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Healthcare Diagnostics Products, Ltd.
- Headquarters
- Not reported
- Brand website
- siemens-healthineers.com
- FDA applicant address
- Glyn Rhonwy, Llanberis, LL55 4EL
Sources and methodology
- Original FDA record: P010051/S023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


